Previously, Grau-Lopez et al. detected a positive proliferative reaction to a mix of seven myelin-derived peptides (MBP13–32, MBP111–129, MBP146–170, MBP83–99, MOG1–20, MOG35–55 and PLP139–154) in 74% of MS patients [37]. The gene discussed is RANGRF; the disease is myeloid sarcoma.